Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a drug called sigvotatug vedotin SGN-B6A alone and in combination with pembrolizumab, with or without chemotherapy, to assess its safety and effects in people with advanced solid tumors. This Phase 1 study aims to determine the side effects and whether sigvotatug vedotin works to treat various solid tumors including lung, head and neck, breast, esophageal, skin, pancreatic, bladder, cervical, gastric, and ovarian cancers. The study is divided into four parts to explore dosage, safety, and combination treatments. Participants may receive sigvotatug vedotin alone or combined with pembrolizumab, sometimes alongside chemotherapy drugs carboplatin or cisplatin, depending on the study part. Part A focuses on finding the right dose of sigvotatug vedotin. Part B uses this dose to further test safety and effectiveness. Parts C and D study the drug combined with pembrolizumab and possibly chemotherapy in different tumor types and treatment settings, including people who have not previously received treatment. Treatments are given intravenously, with pembrolizumab administered every 3 or 6 weeks and chemotherapy every 3 weeks. During the study, participants undergo tumor biopsies, clinical evaluations, and monitoring for side effects, including blood tests and safety assessments. Researchers track adverse events, lab abnormalities, and dose-limiting toxicities up to 30-37 days after treatment, with some follow-up extending up to 3 years. They also measure tumor response using standard criteria and monitor survival and drug levels in the body. Participants will have regular visits for treatment and assessments throughout the study duration, which may last several years.
Actively Recruiting
Researchers are evaluating the safety, pharmacokinetics, immune response, and early effects of the investigational drug DMR-001 in adults with CALR-mutated myeloproliferative neoplasms, including essential thrombocythemia ET and myelofibrosis MF. The study also assesses DMR-001 combined with ruxolitinib in patients with CALR-mutant MF. This Phase 11b open-label study aims to determine recommended dosing levels and preliminary clinical activity. DMR-001 is given as a subcutaneous injection once every four weeks in several parts of the trial an initial dose escalation phase to find safe doses, a dose expansion phase using those doses, and a combination phase where DMR-001 is administered with ruxolitinib, an approved oral therapy for MF. The combination and monotherapy dosing schedules are carefully monitored to identify the maximum tolerated doses and recommended doses for future studies. Participants will be closely monitored for safety and treatment effects for up to 672 days. This includes laboratory tests, bone marrow biopsies, and pharmacokinetic assessments to measure drug levels and immune response. Researchers will assess tolerability, clinical activity, and immune reactions to DMR-001 alone or combined with ruxolitinib. The study involves regular visits for treatment administration and safety evaluations, ensuring continuous observation throughout the trial period.
Actively Recruiting
Researchers are conducting a Phase 2 trial to compare TP-06 2.0% ophthalmic solution with a placebo vehicle in adults who have persistent corneal epithelial defects PCED that have not healed after at least 10 days of standard treatment. This trial aims to evaluate the safety and effectiveness of TP-06 in promoting corneal healing, improving visual acuity, and assessing changes in corneal thickness. Participants will be randomly assigned to receive either TP-06 2.0% or the vehicle four times daily for 8 weeks, alongside required background therapy. After the treatment phase, there will be a 2-week follow-up period to monitor healing and safety. The study is double-masked and involves multiple centers. During the study, participants will undergo assessments including evaluation of corneal healing through fluorescein staining, measurement of lesion size with imaging, and tests of visual acuity. Researchers will monitor the timing and extent of corneal healing and any safety concerns. The total participation time includes 8 weeks of treatment plus 2 weeks of follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of fusidic acid 1% eye drops compared to a placebo for treating bacterial conjunctivitis in both adults and children. This Phase 3 clinical trial aims to show that fusidic acid 1% is superior to placebo in curing bacterial conjunctivitis and to further confirm its safety when applied topically to the eyes. Participants will be randomly assigned to one of two groups one group will apply one drop of fusidic acid 1% in each eye twice daily for seven days, and the other group will use a placebo eye drop with the same schedule. The doses are ideally spaced about 12 hours apart, but the twice-daily application schedule is prioritized over exact timing. During the study, participants will be assessed for clinical cure and microbial eradication at Day 4 and Day 8 visits. Researchers will monitor safety and treatment effects through these evaluations and by tracking any adverse events. The total participation duration covers at least the seven days of treatment plus follow-up assessments, helping establish both effectiveness and safety profiles for the treatment.
Actively Recruiting
This research aims to review anonymous medical records to study the clinical outcomes of various treatments for chronic pain. It is a retrospective, multi-center data review that includes multiple patient groups to evaluate different treatment approaches. The study focuses on patients who have been implanted with or are eligible for spinal cord stimulation systems or other treatments such as radiofrequency RF or intrathecal drug delivery systems IDS. The study compares different treatment methods, including Boston Scientific devices and non-Boston Scientific systems like spinal cord stimulation, RF, and IDS. It involves two groups patients eligible for these treatments and those who have received a prior treatment followed by a different chronic pain therapy. This evaluation uses de-identified data collected from medical charts without direct patient intervention. Participants involvement consists of reviewing their past medical data over approximately two years. Researchers will measure the responder rate, which indicates the effectiveness of the treatments through the study period. Since this is a data review, there are no active treatments or visits required, and patient privacy is maintained throughout the study.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of using circulating tumor DNA ctDNA testing with the Signatera Genome assay to guide the start of CDK46 inhibitor therapy in participants with intermediate-risk, early-stage hormone receptor-positive HR, HER2-negative breast cancer. This approach aims to determine if starting CDK46 inhibitors based on ctDNA results can maintain treatment effectiveness while reducing unnecessary medication use, comparing outcomes to historical data from the NataLEE trial. Participants will undergo ctDNA testing every three months for up to four years. Those testing positive for ctDNA at baseline or during surveillance will start CDK46 inhibitor therapy either ribociclib or abemaciclib combined with hormone therapy for at least two years. Participants who remain ctDNA negative will continue hormone therapy alone with ongoing ctDNA monitoring. Treatment choices follow standard care guidelines and continue until disease progression, unacceptable side effects, or study end. During the study, participants will have regular blood draws for ctDNA testing, hormone therapy, and imaging as needed. Researchers will monitor invasive disease-free survival for up to nine years after surgery. Quality of life assessments and ongoing safety monitoring are part of the follow-up, which will last up to nine years to fully assess cancer outcomes and compare with historical controls.
Actively Recruiting
Researchers are evaluating the effectiveness of petosemtamab combined with chemotherapy compared to cetuximab combined with chemotherapy in treating left-sided colorectal cancer that cannot be removed by surgery or has spread to other parts of the body. This Phase 3, randomized, open-label global trial involves participants with RAS and BRAF wild-type tumors, aiming to assess treatment safety and efficacy as a first-line therapy. Participants will receive either petosemtamab plus one of two chemotherapy options mFOLFOX6 or FOLFIRI or cetuximab plus the same chemotherapy choices. Treatments are administered via intravenous infusions. The study treatment duration varies per participant, continuing as long as the cancer remains stable or improves without serious issues. Treatment cycles last 4 weeks, with participants attending two clinic visits per cycle for monitoring. During the study, participants will undergo blood tests and imaging to check treatment safety and effectiveness. Researchers will measure outcomes such as progression-free survival and objective response rate up to about 35 months, and additional measures like overall survival and quality of life up to about 62 months. The total time involved in the study, including screening, treatment, and follow-up, depends on each participants individual course.
Actively Recruiting
Researchers are evaluating overall survival in patients with advanced metastatic or locally recurrent breast cancer who have no approved alternative therapies available. This Phase 3, multicenter, randomized, open-label study compares the Bria-IMT regimen combined with the checkpoint inhibitor Retifanlimab against treatment chosen by patients or physicians, known as Treatment of Physicians Choice TPC. The study also investigates the activity of the Bria-IMT regimen alone compared to its combination with Retifanlimab. Participants are initially randomized into three groups Bria-IMT regimen plus Retifanlimab combination therapy, TPC, and Bria-IMT regimen alone monotherapy. After enrolling the first 150 patients, the monotherapy group will be discontinued, and those patients may switch to combination therapy. The Bria-IMT regimen includes cyclophosphamide administered 2-3 days before SV-BR-1-GM given intradermally in four inoculations, followed by checkpoint inhibitor infusion plus interferon injections at inoculation sites over three days. Treatment cycles repeat every three weeks, while TPC is given per standard care at each site. Imaging assessments are conducted every six weeks twice, then every eight weeks thereafter unless disease progression or safety issues occur. During the study, participants will have regular therapy cycles and imaging assessments to monitor disease progression. Researchers will evaluate outcomes such as overall survival up to 60 months, progression-free survival, clinical benefit rate, overall response rate, quality of life, and central nervous system event-free survival. Safety and treatment effects will be closely monitored throughout the trial, which is expected to complete by June 2028.
Actively Recruiting
Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.
Actively Recruiting
Researchers are evaluating the cancer vaccine OSE2101 compared to the chemotherapy drug docetaxel in patients with metastatic non-small cell lung cancer NSCLC who have developed resistance to immune checkpoint inhibitors. This phase 3, randomized, open-label study focuses on HLA-A2 positive patients with either squamous or non-squamous NSCLC who are not candidates for surgery or radiation and lack certain genetic alterations that make them eligible for targeted therapies. Participants will be randomly assigned in a 21 ratio to receive either OSE2101 or docetaxel. OSE2101 is given as a subcutaneous injection every three weeks for six cycles, then every eight weeks for the first year, and finally every twelve weeks until the end of the second year. Docetaxel is administered as an intravenous infusion every three weeks. The study also uses companion diagnostic devices to confirm HLA-A2 status. Throughout the study, participants will have regular visits for treatment and monitoring. Researchers will measure overall survival from randomization until death, with an average follow-up of three years. The trial aims to assess the safety and effectiveness of OSE2101 compared to docetaxel in this patient group, with ongoing monitoring until study completion in late 2028.